Dogwood secures royalty free rights to SP16 for cancer related pain

Shares of US clinical-stage biotech Dogwood Therapeutics (Nasdaq: DWTX) soared a massive 43% to $7.91 yesterday, on the news it has secured a royalty free, global license to develop Serpin Pharma’s intravenous (IV) formulation of SP16 to manage cancer related pain (CRP) including a broad range of chemotherapy induced neuropathy symptoms.

Serpin Pharma has discovered the active portion of A1AT responsible for both the anti-inflammatory (analgesic) activity as well as tissue repair, and this active portion is represented by SP16. SP16 is a first-in-class LRP1 agonist which has demonstrated both anti-inflammatory and neural repair activity that has the potential to treat chemotherapy-induced peripheral neuropathy (CIPN). SP16 IV is the focus of a forthcoming Phase Ib CIPN study that is fully funded by the National Cancer Institute, reflecting the uniqueness of this approach, as well as the extraordinary unmet medical need associated with this debilitating cancer-related condition.

The global cancer-related pain (CRP) treatment market size was valued at approximately $8.35 billion in 2025 and is projected to reach around $11.24 billion by 2030, according to Resear0ch and Markets. Other reports provide slightly different values, with some estimating the 2024 market at around $8.6 billion and a forecast of $14.4 billion by 2033, while others place the 2024 value at $8.45 billion with an expected reach of $12.32 billion by 2030.